CCNE1 — gene · CancerIndex

Curated evidence

Clinical evidence (17)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–17 of 17 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CCNE1 Amplification9
(prognostic)	Ovarian Carcinoma	Prognostic	B	Supports Poor Outcome	4	accepted	EID466 In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival.

Cohorts

Alteration frequency by cohort (20)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved20 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Upper Tract Urothelial Carcinoma PDX (MSK, Nat Commun 2020) utuc_pdx_msk_2019	Renal Pelvis and Ureter Urothelial Carcinoma	Ssm

Literature

Linked publications (8)

25 per page, newest first.

pubmedPublishedShowing 1–8 of 8 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Cyclin E and survival in patients with breast cancer.
· N Engl J Med · 2002 · PMID 12432043 · validated civic_curation pubmed
Cyclin E in human cancers.
· FASEB J · 1999 · PMID 10224221 · validated civic_curation pubmed
Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
· Cancer · 2010 · PMID 20336784 · validated civic_curation pubmed
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
· J Clin Oncol · 2019 · PMID 30807234 · validated civic_curation pubmed

CCNE1 Overexpression7
(prognostic)	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	4	accepted	EID363 Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times hig… (full text at CIViC) PMID 12432043 · Keyomarsi et al., 2002 · Open in CIViC	civic
〃	Gastric Adenosquamous Carcinoma	Prognostic	B	Supports Poor Outcome	4	rejected	EID364 Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma. PMID 10224221 · Donnellan et al., 1999 · Open in CIViC	civic
〃	Gastric Adenosquamous Carcinoma	Prognostic	B	Supports Poor Outcome	4	accepted	EID365 Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma. PMID 10224221 · Donnellan et al., 1999 · Open in CIViC	civic
CDK Inhibitor SNS-032	Malignant Ovarian Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID1734 Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression. SNS-032 greatly prolonged the surviva… (full text at CIViC) PMID 26204491 · Yang et al., 2015 · Open in CIViC	civic
Palbociclib	Malignant Ovarian Neoplasm	Predictive	D	Supports Resistance	3	submitted	EID7792 The effect of high CCNE1 expression on PD0332991 (palbociclib) sensitivity was observed in cell lines. One PD0332991 sensitive cell line, HEY, was engineered to constitutively express CCNE1 (HEY-CCNE… (full text at CIViC) PMID 25557169 · Taylor-Harding et al., 2015 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	3	submitted	EID10182 Breast cancer cell lines derived from T-47D (vector control, overexpress cyclin E1, overexpress cyclin E2) were treated with CDK4/6 inhibitor PD0332991 and CDK2 inhibitor SNS-032 as single agents and … (full text at CIViC) PMID 22564725 · Caldon et al., 2012 · Open in CIViC	civic
CDK Inhibitor SNS-032 + PalbociclibCombination	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	3	submitted	EID10183 Breast cancer cell lines derived from T-47D (vector control, overexpress cyclin E1, overexpress cyclin E2) were treated with CDK4/6 inhibitor PD0332991 and CDK2 inhibitor SNS-032 as single agents and … (full text at CIViC) PMID 22564725 · Caldon et al., 2012 · Open in CIViC	civic